Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esophageal carcinoma following trimodality therapy: a case report

Davide Adriano Santeufemia¹, Salvatore Tumolo¹, Antonino De Paoli², Giovanni Lo Re¹, Gianni Boz², Gian Maria Miolo³, Tanja Baresic², Stefano Maria Massimiliano Basso¹, and Roberto Innocente²

¹Medical Oncology Santa Maria degli Angeli Hospital, Pordenone. ²Department of Radiation Oncology. ³Department of Medical Oncology. Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy

ABSTRACT

Background. Esophageal cancer (EC) patients presenting a local recurrence following trimodality therapy (chemoradiation and surgery) have limited palliative treatment options when the three major modalities of therapy have been exhausted. In addition, some patients experience a local recurrence or develop a metachronous cancer in a previously irradiated site, without evidence of systemic disease. For these patients there is a potential for cure, although the risk of further distant recurrences remains high.

Case report. We report of a successful concomitant chemo/SBRT treatment in a case of locally advanced metachronous squamous cervical EC, which was diagnosed in a patient previously treated with trimodality therapy for a squamous tonsillar carcinoma.

Result. Chemo/SBRT seems to be a reasonable salvage option for patients without distant metastases who have exhausted standard therapies.

Conclusions. Our experience also suggests that a concomitant chemo/SBRT treatment appears to be either feasible or effective and chemo/SBRT can be considered also in selected patients affected by EC with squamous histology and with neoplastic infiltration of the trachea.

Key words: esophageal cancer, tomotherapy, recurrence.

Correspondence to: Davide Adriano Santeufemia, MD, SOC Oncology Santa Maria degli Angeli Hospital, via Monteralle 34, 33170 Pordenone, Italy. Tel +39-043-4399796; fax +39-043-4399187; email davidesanteufemia@gmail.com

Received August 18, 2011; accepted November 3, 2011.